A Phase 2, Multicentre, Randomized, Double-blind, Placebo-controlled Study in Patients With New-onset Type 1 Diabetes

C-peptide level is a widely used measure of pancreatic beta-cell function. The MMTT is one of the methods for its estimation. The MMTT was performed after an overnight fast, at baseline (within 1 week prior to randomization), and at each follow-up visit on weeks 13±1, 26±2, and 52±2. Prior to the test, patients withheld long-acting insulin on the morning of the test. Rapid-acting and short-acting insulin were allowed up to 6hrs and 2 hrs, respectively, before the test. The test was rescheduled if the patient had a capillary glucose value of \>200mg/dL or \<70mg/dL. After 2 pre-meal basal samples had been drawn between -20 to 0 min (basal 1 and basal 2), patients were given 6mL/kg of Boost® High Protein Nutritional Drink up to a maximum of 360mL, to be drunk within 5 min. Post-meal samples were drawn at 15, 30, 60, 90, 120 min after the meal at week 13+/-1 The 2-hour C-peptide AUC after the MMTT at Week 13±1 was transformed as log(x+1) values.

Time frame: week 13±1

Population: ITT population: all patients who were randomised and received at least 1 dose of study treatment (either ladarixin or placebo)

A subgroup analysis of efficacy endpoints by fasting C-peptide at Screening was performed. The reported data specifically refers to fasting C-peptide at Screening \<median value. All the AUC analyses were based on actual rather than scheduled timings and were calculated using the trapezoidal rule. If the actual time was not recorded, the scheduled time was used instead. Post-meal samples were drawn at 15, 30, 60, 90, 120 min after the meal. The 2-hour C-peptide AUC after the MMTT was transformed as log(x+1) values.

Time frame: Follow-up at Weeks 13±1, 26±2, and 52±2.

Population: ITT population: all patients who were randomised and received at least 1 dose of study treatment (either ladarixin or placebo).~Please note that the number of participants analysed represents the number of patients contributing to summary statistics.

C-peptide level is a widely used measure of pancreatic beta-cell function. The MMTT is one of the methods for its estimation. The MMTT was performed after an overnight fast, at baseline (within 1 week prior to randomization), and at each follow-up visit on weeks 13±1, 26±2, and 52±2. Prior to the test, patients withheld long-acting insulin on the morning of the test. Rapid-acting and short-acting insulin were allowed up to 6hrs and 2 hrs, respectively, before the test. The test was rescheduled if the patient had a capillary glucose value of \>200mg/dL or \<70mg/dL. After 2 pre-meal basal samples had been drawn between -20 to 0 min (basal 1 and basal 2), patients were given 6mL/kg of Boost® High Protein Nutritional Drink up to a maximum of 360mL, to be drunk within 5 min. Post-meal samples were drawn at 15, 30, 60, 90, 120 min after the meal at week 13+/-1. The 2-hour C-peptide AUC after the MMTT at Week 13±1 was transformed as log(x+1) values.

Time frame: Follow-ups at Weeks 26±2 and 52±2

Population: ITT population: all patients who were randomised and received at least 1 dose of study treatment (either ladarixin or placebo).~Please note that the number of participants analysed represents the number of patients contributing to summary statistics.

A subgroup analysis of efficacy endpoints by fasting C-peptide at Screening was performed. The reported data specifically refers to fasting C-peptide at Screening \<median value. All the AUC analyses were based on actual rather than scheduled timings and were calculated using the trapezoidal rule. If the actual time was not recorded, the scheduled time was used instead. Post-meal samples were drawn at 15, 30, 60, 90, 120 min after the meal at Weeks 13±1, 26±2, and 52±2.

Time frame: Follow-up at Weeks 13±1, 26±2, and 52±2.

Population: ITT population: all patients who were randomised and received at least 1 dose of study treatment (either ladarixin or placebo).~Please note that the number of participants analysed represents the number of patients contributing to summary statistics.

Time points at each visit are Basal 1 and Basal 2 (samples collected at -20 and 0 min, respectively; Here are reported the following timepoints: Basal average (which is the average of Basal 1 and Basal 2), 15, 30, 60, 90, 120, and 180 minutes after the meal. For values at each time point see below.

Time frame: Baseline, follow-ups at Weeks 13±1, 26±2, and 52±2

Population: ITT population = all patients who were randomised and received at least 1 dose of study treatment (either ladarixin or placebo).~Please note that the number of participants analysed represents the number of patients contributing to summary statistics.

Time points at each visit are Basal 1 and Basal 2 (samples collected at -20 and 0 min, respectively). Here are reported the following timepoints: Basal average (which is the average of Basal 1 and Basal 2), 15, 30, 60, 90, 120, and 180 minutes after the meal. For values at each time point see below.

Time frame: Baseline, follow-ups at Weeks 13±1, 26±2, and 52±2

Population: ITT population = all patients who were randomised and received at least 1 dose of study treatment (either ladarixin or placebo).~Please note that the number of participants analysed represents the number of patients contributing to summary statistics.

Insulin requirement (IU/kg/day averaged over the previous 3 days) was to be recorded in the interval from randomization to Week 13±1, Week 13±1 to Week 26±2, and Week 26±2 to Week 52±2. From enrolment, patients were admitted to intensive diabetes management, according to current ADA recommendation \[2014\]. Patients were instructed to self-monitor their glucose values at least 4 times a day and to report (glucose meter/log) outcome to the diabetes management team. Insulin intake was adjusted to target HbA1c levels of less than 7% and self-monitored (fingerstick): * pre-prandial blood glucose of 70-130 mg/dL * post-prandial blood glucose \< 180 mg/dL * bed-time blood glucose of 110-150 mg/dL Telephone calls (outside scheduled visits) were scheduled on a regular basis to ensure optimization of metabolic control.

Time frame: Follow-ups at Weeks 13±1, 26±2 and 52±2

Population: ITT population = all patients who were randomised and received at least 1 dose of study treatment (either ladarixin or placebo).~Please note that the number of participants analysed represents the number of patients contributing to summary statistics.

HbA1c measurement can be used as a diagnostic test for diabetes providing that stringent quality assurance tests are in place and assays are standardised to criteria aligned to the international reference values, and there are no conditions present which preclude its accurate measurement. An HbA1c of 6.5% is recommended as the cut point for diagnosing diabetes. A value of less than 6.5% does not exclude diabetes diagnosed using glucose tests.

Time frame: Follow-ups at Weeks 13±1, 26±2 and 52±2

Population: ITT population = all patients who were randomised and received at least 1 dose of study treatment (either ladarixin or placebo).~Please note that the number of participants analysed represents the number of patients contributing to summary statistics.

The means are all adjusted means. The MMTT over the study: logAUC(15-120 min) of C-peptide above fasting value at Weeks 13±1, 26±2, and 52±2 is reported. Post-meal samples were drawn at 15, 30, 60, 90, 120 min after the meal at weeks 13+/-1, 26±2 and 52±2

Time frame: Follow-ups at Weeks 13±1 26±2 and 52±2

Population: ITT population: all patients who were randomised and received at least 1 dose of study treatment (either ladarixin or placebo).~Please note that the number of participants analysed represents the number of patients contributing to summary statistics.

A severe hypoglycaemic event was defined as an event with one of the following symptoms: memory loss, confusion, uncontrollable behaviour, irrational behaviour, unusual difficulty in awakening, suspected seizure, seizure, loss of consciousness, or visual symptoms, in which the patient was unable to treat him/herself and which was associated with either a blood glucose level \<54 mg/dL or prompt recovery after oral carbohydrate, i.v. glucose, or glucagon administration.

Time frame: Follow-ups at Weeks 13±1, 26±2 and 52±2

Population: ITT population = all patients who were randomised and received at least 1 dose of study treatment (either ladarixin or placebo).~Please note that the number of participants analysed represents the number of patients contributing to summary statistics.

C-peptide level is a widely used measure of pancreatic beta-cell function. The MMTT is one of the methods for its estimation. The MMTT was performed after an overnight fast, at baseline (within 1 week prior to randomization), and at each follow-up visit on weeks 13±1, 26±2, and 52±2. Prior to the test, patients withheld long-acting insulin on the morning of the test. Rapid-acting and short-acting insulin were allowed up to 6hrs and 2 hrs, respectively, before the test. The test was rescheduled if the patient had a capillary glucose value of \>200mg/dL or \<70mg/dL. The test was initiated before 10 a.m. After 2 pre-meal basal samples had been drawn between -20 to 0 min (basal 1 and basal 2), patients were given 6mL/kg of Boost® High Protein Nutritional Drink (Nestlé Nutrition) up to a maximum of 360mL, to be drunk within 5 min. Post-meal samples were drawn at 15±5, 30±5, 60±10, 90±10, 120±15, 180±15 min after the meal.

Time frame: Follow-ups at Weeks 13±1, 26±2 and 52±2

Population: ITT population = all patients who were randomised and received at least 1 dose of study treatment (either ladarixin or placebo).~Please note that the number of participants analysed represents the number of patients contributing to summary statistics.

Maintenance of a residual ß-cell function is defined as at least one MMTT C-peptide value \> 0.2 nmol/L. Proportion is reported as Percentage of patients.

Time frame: Follow-ups at Weeks 13±1, 26±2 and 52±2

Population: ITT population = all patients who were randomised and received at least 1 dose of study treatment (either ladarixin or placebo)

A severe hypoglycaemic event was defined as an event with one of the following symptoms: memory loss, confusion, uncontrollable behaviour, irrational behaviour, unusual difficulty in awakening, suspected seizure, seizure, loss of consciousness, or visual symptoms, in which the patient was unable to treat him/herself and which was associated with either a blood glucose level \<54 mg/dL or prompt recovery after oral carbohydrate, i.v. glucose, or glucagon administration. Proportion is reported as percentage of patients. Events per patient are calculated from the date of randomisation.

Time frame: Follow-ups at Weeks 13±1, 26±2 and 52±2

Population: ITT population = all patients who were randomised and received at least 1 dose of study treatment (either ladarixin or placebo)

A severe hypoglycaemic event was defined as an event with one of the following symptoms: memory loss, confusion, uncontrollable behaviour, irrational behaviour, unusual difficulty in awakening, suspected seizure, seizure, loss of consciousness, or visual symptoms, in which the patient was unable to treat him/herself and which was associated with either a blood glucose level \<54 mg/dL or prompt recovery after oral carbohydrate, i.v. glucose, or glucagon administration. Proportion is reported as percentage of patients, despite the measure type indicated is number. Events per patient are calculated from the date of randomisation.

Time frame: Follow-up at Weeks 13±1, 26±2, and 52±2

Population: ITT population: all patients who were randomised and received at least 1 dose of study treatment (either ladarixin or placebo).~Please note that the number of participants analysed represents the number of patients contributing to summary statistics.